PhalconBio is pleased to announce its entry into a Stage I partnership with the INcubator for Clinical Antibacterial Therapies in Europe (INCATE). INCATE unites translational and basic research, industry experts, seasoned entrepreneurs, and investors from across Europe to accelerate the growth of innovative start-ups tackling antimicrobial resistance (AMR). By joining INCATE, PhalconBio is proud to become part of a dynamic and collaborative community.

‍

Dr. Samuel Kilcher, Co-founder and CSO of PhalconBio, shared his enthusiasm:
“INCATE is an outstanding initiative that provides invaluable support to small biotech companies like ours. Their expertise, coupled with a vibrant community of start-ups and experienced professionals across diverse disciplines, is instrumental in driving our success. We are especially grateful for INCATE’s guidance, which strengthens our regulatory strategy and bolsters our efforts to address the global AMR challenge.”

‍